Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).
It is very uncertain whether autologous blood or PRP changes treatment success (> 25% improvement in pain or function) compared with placebo at 3 months' follow‐up (very low certainty).
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).
Surfactant administration via thin catheter (S‐TC) probably leads to lower death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual… compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
Surfactant administration via thin catheter (S‐TC) probably leads to lower need for intubation within the first 72 hours compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
Surfactant administration via thin catheter (S‐TC) showed no clear difference in air leak requiring drainage compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
Surfactant administration via thin catheter (S‐TC) may leads to lower severe intraventricular haemorrhage (grade III or IV) compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
Surfactant administration via thin catheter (S‐TC) may leads to lower death during first hospitalisation (all causes) compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
Surfactant administration via thin catheter (S‐TC) probably leads to lower bronchopulmonary dysplasia (BPD) among survivors at 36 weeks'… compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
The review found no eligible studies for this question.
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).